Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0499 Transporter Info | ||||
| Gene Name | SLCO1C1 | ||||
| Protein Name | Organic anion transporting polypeptide 1C1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs3794271 | ||||
| Site of GPD | chr12:20707159 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | G=0.4243/2125 (Global) | ||||
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 13 Drugs in Total | ||||
| Infliximab | Drug Info | Rheumatoid Arthritis | Correlated with the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Adalimumab | Drug Info | Rheumatoid Arthritis | Irrelevant to the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Etanercept | Drug Info | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Adalimumab | N.A. | Multiple Myeloma | Allele G is not associated with decreased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele A. | [ 1] | |
| Infliximab | N.A. | Multiple Myeloma | Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A. | [ 1] | |
| Etanercept | N.A. | Multiple Myeloma | Allele G is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Multiple Myeloma | Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Treatment Failure | Allele G is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid. | [ 2] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Arthritis, Psoriatic | Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Rheumatoid Arthritis | Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Arthritis, Psoriatic | Allele G is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid. | [ 2] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Rheumatoid Arthritis | Allele G is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid. | [ 2] | |
| Tumor necrosis factor alpha (Tnf-Alpha) inhibitors | N.A. | Rheumatoid Arthritis | Correlated with the decreased drug response in patients (compare with Allele A) | [ 1] | |
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 10 Drugs in Total | ||||
| Infliximab | Drug Info | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 3] | |
| Infliximab | Drug Info | Psoriasis | Correlated with the increased drug response in patients (compare with genotype AA) | [ 4] | |
| Etanercept | Drug Info | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 3] | |
| Etanercept | Drug Info | Psoriasis | Correlated with the increased drug response to tumor necrosis factor alpha (tnF-alpha) inhibitors in patients (compare with genotype AA) | [ 4] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Treatment Failure | Genotypes AG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA. | [ 4] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Treatment Failure | Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic as compared to genotype AA. | [ 3] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Arthritis, Psoriatic | Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic as compared to genotype AA. | [ 3] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Rheumatoid Arthritis | Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic as compared to genotype AA. | [ 3] | |
| Tumor necrosis factor alpha (Tnf-Alpha) inhibitors | N.A. | Psoriatic Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 3] | |
| Tumor necrosis factor alpha (Tnf-Alpha) inhibitors | N.A. | Psoriasis | Correlated with the increased drug response in patients (compare with genotype AA) | [ 4] | |
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Infliximab | N.A. | Treatment Failure | Genotype GG is associated with decreased likelihood of treatment failure when treated with infliximab in people with Crohn Disease as compared to genotypes AA + AG. | [ 5] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Arthritis, Psoriatic | Patients with the GG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Rheumatoid Arthritis | Patients with the GG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | [ 1] | |
| Genotype AA | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Arthritis, Psoriatic | Patients with the AA genotype and arthritis may have increased response to TNF inhibitors as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Rheumatoid Arthritis | Patients with the AA genotype and arthritis may have increased response to TNF inhibitors as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | [ 1] | |
| Genotype AG | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Arthritis, Psoriatic | Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | [ 1] | |
| Tumor Necrosis Factor Alpha (tnf-alpha) Inhibitors | N.A. | Rheumatoid Arthritis | Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment. | [ 1] | |
| References | |||||
| 1 | GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013 May;14(7):727-34. | ||||
| 2 | Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics. 2016 May;17(7):715-20. | ||||
| 3 | PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics. 2014 Nov;15(14):1763-1769. | ||||
| 4 | Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J. 2015 Aug;15(4):322-5. | ||||
| 5 | Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease. Biomed Pharmacother. 2023 Mar;159:114225. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.